Cannabidiol in epilepsy: The indications and beyond

Epilepsy, although common, remains difficult to treat with as much as 30% of patients having treatment-resistant conditions. Lennox-Gastaut syndrome and Dravet syndrome are childhood-onset epilepsies and among the most difficult to treat. Cannabidiol has been approved by the Food and Drug Administra...

Descripción completa

Detalles Bibliográficos
Autor principal: Ryan, Melody
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2020
Materias:
Psychopharmacology Pearls
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653733/
https://www.ncbi.nlm.nih.gov/pubmed/33224689
http://dx.doi.org/10.9740/mhc.2020.11.317
Descripción
Sumario:Epilepsy, although common, remains difficult to treat with as much as 30% of patients having treatment-resistant conditions. Lennox-Gastaut syndrome and Dravet syndrome are childhood-onset epilepsies and among the most difficult to treat. Cannabidiol has been approved by the Food and Drug Administration to treat these conditions in individuals over 2 years of age; however, there is a great deal of interest in off-label use. This article examines 3 cases: 1 of a patient with Lennox-Gastaut syndrome, 1 of off-label use of cannabidiol to treat epilepsy, and 1 of nonprescription forms of cannabidiol to treat epilepsy.

Ejemplares similares